Trend Following
(11)
▼
Momentum
(6)
▼
Volatility
(5)
▼
Pattern Recognition
(5)
▼
Mean Reversion
(4)
▼
Volume Based
(5)
▼
Advanced
(10)
▼
CELZ
$1.81
$
Creative Medical Technology Holdings, Inc., a biotechnology company, focuses on immunology, urology, orthopedics, and neurology using adult stem cell treatments. The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; StemSpine to treat chronic lower back pain; ImmCelz for the treatment of stroke patients; and OvaStem for treatment of female infertility. Creative Medical Technology Holdings, Inc. is based in Phoenix, Arizona.
Beta
2.067
Average Volume
Market Cap
Last Dividend
CIK
0001187953
ISIN
US22529Y4089
CUSIP
22529Y200
CEO
Timothy Warbington
Sector
Healthcare
Industry
Biotechnology
Full Time Employees
4
IPO Date
2015-11-06
Status
Active
Latest News
| Title | Headline | Publisher | Date |
|---|---|---|---|
| Creative Medical Technology Holdings Reaches Major Clinical Inflection Point with Positive Interim Data from ADAPT Trial and CELZ-201 (Olastrocel) in the Treatment of Chronic Lower Back Pain | Data Show Strong Functional and Pain Improvements Supported by Excellent Safety Profile Data Show Strong Functional and Pain Improvements Supported by Excellent Safety Profile | GlobeNewsWire | 2026-01-13 09:15:00 |
| Creative Medical Technology Holdings Receives Regulatory Approval for BioDefense Burn Pit Initiative | PHOENIX, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) (“Creative Medical” or the “Company”), a clinical-stage biotechnology company advancing regenerative medicine and AI-enabled biodefense solutions, today announced that its BioDefense Inc. Burn Pit Initiative has received regulatory approval to proceed, marking a significant milestone in the Company's mission to address the long-term health consequences of toxic burn pit exposure among U.S. military veterans. | GlobeNewsWire | 2026-01-06 09:15:00 |
| Creative Medical Technology Holdings, Inc. Completes Enrollment in FDA-Cleared ADAPT Trial for CELZ-201-Olastrocel, Marking Major Clinical Inflection Point | Completion of Enrollment Positions CELZ for Near-Term Data Catalysts and Accelerates Path Toward Commercialization of a Transformative, Non-Opioid Therapy for Chronic Lower Back Pain Completion of Enrollment Positions CELZ for Near-Term Data Catalysts and Accelerates Path Toward Commercialization of a Transformative, Non-Opioid Therapy for Chronic Lower Back Pain | GlobeNewsWire | 2025-12-17 09:15:00 |
| Creative Medical Technology Holdings Announces World Health Organization Approval of “olastrocel” as INN for Lead Allogeneic Cell Therapy CELZ-201 | Global assignment of this unique name enhances international clarity, strengthens regulatory positioning, and supports olastrocel's advancement across large unmet-need global markets Global assignment of this unique name enhances international clarity, strengthens regulatory positioning, and supports olastrocel's advancement across large unmet-need global markets | GlobeNewsWire | 2025-12-02 09:15:00 |
SEC Filings
| Type | Filing Date | Accepted Date | Link |
|---|---|---|---|
| 8-K | 2025-12-31 | 2025-12-31 | View Filing |
| 8-K | 2025-12-19 | 2025-12-19 | View Filing |
| 424B3 | 2025-12-16 | 2025-12-16 | View Filing |
| EFFECT | 2025-12-12 | 2025-12-15 | View Filing |
| S-3 | 2025-11-21 | 2025-11-21 | View Filing |
| DEF 14A | 2025-11-13 | 2025-11-13 | View Filing |
| 8-K | 2025-11-12 | 2025-11-12 | View Filing |
| 10-Q | 2025-11-07 | 2025-11-07 | View Filing |
| PRE 14A | 2025-11-03 | 2025-11-03 | View Filing |
| 8-K | 2025-10-31 | 2025-10-31 | View Filing |
| DEF 14A | 2025-10-30 | 2025-10-30 | View Filing |
| SC 13G/A | 2025-08-14 | 2025-08-14 | View Filing |
| 10-Q | 2025-08-08 | 2025-08-08 | View Filing |
| SC 13G | 2025-05-15 | 2025-05-15 | View Filing |
| 10-Q | 2025-05-09 | 2025-05-09 | View Filing |
| 8-K | 2025-05-06 | 2025-05-06 | View Filing |
| 10-K/A | 2025-04-25 | 2025-04-25 | View Filing |
| 424B3 | 2025-04-15 | 2025-04-15 | View Filing |
| EFFECT | 2025-04-14 | 2025-04-14 | View Filing |
| 8-K | 2025-04-11 | 2025-04-11 | View Filing |
| 10-K/A | 2025-04-04 | 2025-04-04 | View Filing |
| S-3 | 2025-04-02 | 2025-04-02 | View Filing |
| 10-K/A | 2025-03-19 | 2025-03-19 | View Filing |
| DEF 14A | 2025-03-17 | 2025-03-17 | View Filing |
| 8-K | 2025-03-14 | 2025-03-14 | View Filing |
| 10-K | 2025-03-14 | 2025-03-14 | View Filing |
| PRE 14A | 2025-03-07 | 2025-03-07 | View Filing |
| 8-K | 2025-03-07 | 2025-03-07 | View Filing |
| 4 | 2025-02-20 | 2025-02-20 | View Filing |
| 8-K | 2024-12-26 | 2024-12-26 | View Filing |
| 424B3 | 2024-11-20 | 2024-11-20 | View Filing |
| EFFECT | 2024-11-20 | 2024-11-20 | View Filing |
| 10-Q | 2024-11-08 | 2024-11-08 | View Filing |
| S-1 | 2024-11-08 | 2024-11-08 | View Filing |
| DEF 14A | 2024-11-04 | 2024-11-04 | View Filing |
| PRER14A | 2024-10-23 | 2024-10-23 | View Filing |
| 8-K | 2024-10-23 | 2024-10-23 | View Filing |
| 424B5 | 2024-10-23 | 2024-10-23 | View Filing |
| EFFECT | 2024-10-16 | 2024-10-16 | View Filing |
| PRE 14A | 2024-10-04 | 2024-10-04 | View Filing |
| S-3 | 2024-10-04 | 2024-10-04 | View Filing |
| 10-Q | 2024-08-09 | 2024-08-09 | View Filing |
| 8-K | 2024-07-25 | 2024-07-25 | View Filing |
| DEF 14A | 2024-06-05 | 2024-06-05 | View Filing |
| 8-K | 2024-05-17 | 2024-05-17 | View Filing |
| PRE 14A | 2024-05-17 | 2024-05-17 | View Filing |
| 10-Q | 2024-05-10 | 2024-05-10 | View Filing |
| 10-K/A | 2024-04-29 | 2024-04-29 | View Filing |
| 10-K | 2024-03-22 | 2024-03-22 | View Filing |
Algorithm Performance
Upgrade To Premium for Full Access
| Algorithm | Profit/Loss | Profit Factor | # Trades | Sharpe | Sortino | Efficiency |
|---|---|---|---|---|---|---|
| Bull Bias | 32.41% | 1 | 680 | 0.02 | 0.03 | 52.6 |
| Williams PercentR Strategy | 31.58% | 1 | 259 | 0.02 | 0.04 | 51.77 |
| Volatility Squeeze | 17.72% | 1.16 | 34 | 0.05 | 0.12 | 37.92 |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxx | xxxxxxx% | x | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xxx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xxx | xxxx | xxxx | xxxxx |
| xxxxxxxxx | xxxxxxx% | x | xxx | x | xxxx | xxxx |
| xxx | xxxxxx% | x | xxx | x | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xxx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxx | xxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxx | xxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |